Amplia Therapeutics (ASX:ATX) said mature data from its ongoing ACCENT clinical trial in advanced pancreatic cancer showed a median overall survival of 11.1 months and five complete responses to date, with its lead drug candidate narmafotinib combined with chemotherapy, according to a Monday Australian bourse filing.

The company said five patients have achieved a complete response in the Phase 1b/2a trial, resulting in a complete response rate of 7.8%.

The median overall survival of 11.1 months represents a two-month improvement compared to chemotherapy alone, with no additional toxicity burden, the filing added.

Narmafotinib is the company's inhibitor of the protein FAK, which is overexpressed in pancreatic cancer and is gaining "increasing attention" as a drug target in solid tumors, the filing added.

Amplia said it has been chosen to present trial data at the annual meeting of the American Association of Cancer Research (AACR) in San Diego in April.

The company's shares surged past 82% to reach their highest price since August 2025 in recent Monday trade.